Research programme: metabolic disorders antisense therapeutics - UGISense
Latest Information Update: 01 Feb 2023
Price :
$50 *
At a glance
- Originator UGISense
- Class Antihyperglycaemics; Antisense elements; Hepatoprotectants; Obesity therapies; Peptide nucleic acids
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 05 Jan 2023 UGISense has patent protection for its UgimersTM technology platform before January 2023 (UGISense pipeline, January 2023)
- 05 Jan 2023 Early research in Non-alcoholic steatohepatitis in Germany (Parenteral) before January 2023 (UGISense pipeline, January 2023)
- 05 Jan 2023 Early research in Obesity in Germany (Parenteral) before January 2023 (UGISense pipeline, January 2023)